AzTrials
AzTrials

Psoriatic ArthritisPhase 3NCT04908202

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Phase 3 study testing Deucravacitinib in people with Psoriatic Arthritis, run by Bristol-Myers Squibb at 183 sites in 21 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis
What is being tested?
Deucravacitinib
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
670 participants
Where
183 sitesin 21 countries
Study dates
13 Jul 2021to 3 Jun 2027
Phase
Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
  • Meets the Classification Criteria for Psoriatic Arthritis at Screening.
  • Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
  • Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
  • Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
  • ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
  • Must have completed the week 52 treatment for the optional open-label long-term extension period.

Who cannot join

  • Nonplaque psoriasis at screening or day 1.
  • Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.
  • History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).
  • Active fibromyalgia.
  • Received an approved or investigational biologic therapy for the treatment of PsA or PsO.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

183 sites in 21 countries.

183 sites in 21 countries

United States33 sites
  • Local Institution - 0172

    Allen, Texas, 75013

  • Local Institution - 0189

    Amarillo, Texas, 79124

  • Local Institution - 0181

    Beckley, West Virginia, 25801

  • Local Institution - 0087

    Boise, Idaho, 83702

  • Local Institution - 0273

    Bothell, Washington, 98021

  • Local Institution - 0080

    Chicago, Illinois, 60640

  • Local Institution - 0195

    Clearwater, Florida, 33765

  • University Hospitals Cleveland Medical Center-Dermatology

    Cleveland, Ohio, 44106

  • Local Institution - 0185

    Corvallis, Oregon, 97330

  • Local Institution - 0032

    Dallas, Texas, 75231

  • Local Institution - 0170

    Denver, Colorado, 80230

  • Local Institution - 0198

    Detroit, Michigan, 48202

  • Local Institution - 0168

    Fontana, California, 92335

  • Local Institution - 0199

    Fullerton, California, 92835

  • Local Institution - 0171

    Gainesville, Georgia, 30501

  • Local Institution - 0197

    Gilbert, Arizona, 85297

  • Local Institution - 0175

    Greenville, South Carolina, 29601

  • Local Institution - 0042

    Hagerstown, Maryland, 21740

  • Local Institution - 0036

    Jackson, Tennessee, 38305

  • Local Institution - 0188

    Jonesboro, Arkansas, 72401

  • Local Institution - 0268

    Kalispell, Montana, 59901

  • Local Institution - 0083

    Lexington, Kentucky, 40504

  • Local Institution - 0272

    Margate, Florida, 33063

  • Local Institution - 0082

    Miami Lakes, Florida, 33014

  • Local Institution - 0028

    Middleburg Heights, Ohio, 44130

  • Local Institution - 0182

    Oklahoma City, Oklahoma, 73102

  • Local Institution - 0177

    Orland Park, Illinois, 60467

  • Local Institution - 0179

    Perrysburg, Ohio, 43551

  • Local Institution - 0038

    Sacramento, California, 95815

  • Local Institution - 0178

    Schaumburg, Illinois, 60195

  • Local Institution - 0201

    Springfield, Missouri, 65807

  • Cohen Medical Centers

    Thousand Oaks, California, 91360

  • Local Institution - 0186

    Voorhees Township, New Jersey, 08043

Other trials in United States

Poland27 sites
  • Local Institution - 0114

    Bialystok, 15-351

  • Local Institution - 0241

    Częstochowa, Silesian Voivodeship, 42-202

  • Local Institution - 0231

    Dąbrówka, Greater Poland Voivodeship, 62-069

  • Local Institution - 0257

    Gdansk, Pomeranian Voivodeship, 80-382

  • Local Institution - 0234

    Gdynia, Pomeranian Voivodeship, 31-338

  • Local Institution - 0252

    Katowice, Silesian Voivodeship, 40-040

  • Local Institution - 0229

    Krakow, Lesser Poland Voivodeship, 30-149

  • Local Institution - 0126

    Krakow, 30-002

  • Local Institution - 0127

    Krakow, 30-033

  • Local Institution - 0140

    Krakow, 31-501

  • Local Institution - 0238

    Lodz, Łódź Voivodeship, 90-368

  • Local Institution - 0232

    Lublin, Lublin Voivodeship, 20-607

  • Local Institution - 0233

    Nadarzyn, Masovian Voivodeship, 05-830

  • Local Institution - 0206

    Nowy Targ, Lesser Poland Voivodeship, 34-400

  • Local Institution - 0162

    Olsztyn, 10-117

  • Local Institution - 0113

    Poznan, 60-218

  • Local Institution - 0239

    Poznan, 60-702

  • Local Institution - 0112

    Poznan, 60-773

  • Local Institution - 0230

    Świdnik, Lublin Voivodeship, 21-040

  • Local Institution - 0235

    Warsaw, Masovian Voivodeship, 02-665

  • Local Institution - 0243

    Warsaw, Masovian Voivodeship, 02-672

  • Local Institution - 0204

    Warsaw, 00-874

  • Local Institution - 0205

    Warsaw, 02-118

  • Local Institution - 0125

    Warsaw, 03-291

  • Local Institution - 0236

    Wołomin, Masovian Voivodeship, 05-200

  • Local Institution - 0244

    Wroclaw, Lower Silesian Voivodeship, 50-381

  • Local Institution - 0210

    Wroclaw, 52-210

Other trials in Poland

Romania14 sites
  • Local Institution - 0012

    Brasov, 500283

  • Local Institution - 0090

    Bucharest, Bucharest, 011172

  • Local Institution - 0266

    Bucharest, Bucharest, 020125

  • Local Institution - 0167

    Bucharest, 011025

  • Local Institution - 0260

    Bucharest, 014142

  • Local Institution - 0263

    Bucharest, 030463

  • Local Institution - 0184

    Bucharest, 11057

  • Local Institution - 0011

    Cluj-Napoca, 400006

  • Local Institution - 0258

    Craiova, 200347

  • Local Institution - 0262

    Iași, 700127

  • Local Institution - 0265

    Iași, 700661

  • Local Institution - 0264

    Iași, 700714

  • Local Institution - 0010

    Râmnicu Vâlcea, Vâlcea County, 247065

  • Local Institution - 0091

    Timișoara, 300778

Other trials in Romania

Argentina10 sites
  • Local Institution - 0194

    Buenos Aires, 1426

  • Local Institution - 0169

    Buenos Aires, 1428

  • Local Institution - 0192

    Buenos Aires, C1427CCL

  • Local Institution - 0213

    Ciudad Autónoma de Buenos Aires, Buenos Aires, 1111

  • Local Institution - 0046

    Córdoba, Córdoba Province, X5004CDT

  • Local Institution - 0054

    La Plata, Buenos Aires, 1900

  • Local Institution - 0193

    Mendoza, 5500

  • Local Institution - 0215

    Quilmes, Buenos Aires, 1878

  • Local Institution - 0196

    Rosario, Santa Fe Province, S2000

  • Local Institution - 0047

    San Miguel de Tucumán, Tucumán Province, 4000

Other trials in Argentina

Bulgaria10 sites
  • Local Institution - 0253

    Burgas, 8000

  • Local Institution - 0255

    Plovdiv, Plovdiv, 4002

  • Local Institution - 0249

    Plovdiv, 4000

  • Local Institution - 0267

    Plovdiv, 4000

  • Local Institution - 0246

    Plovdiv, 4001

  • Local Institution - 0247

    Plovdiv, 4001

  • Local Institution - 0248

    Sofia, Sofia (stolitsa), 1463

  • Local Institution - 0245

    Sofia, 1505

  • Local Institution - 0259

    Sofia, 1784

  • Local Institution - 0250

    Varna, 9000

Other trials in Bulgaria

Mexico9 sites
  • Local Institution - 0060

    Chihuahua City, 31000

  • Local Institution - 0254

    Guadalajara, Jalisco, 44610

  • Local Institution - 0061

    Mérida, Yucatán, 97070

  • Local Institution - 0212

    Mérida, Yucatán, 97070

  • Local Institution - 0057

    Mexico City, Mexico City, 06720

  • Local Institution - 0209

    Mexico City, 14080

  • Local Institution - 0056

    Saltillo, Coahuila, 25050

  • Local Institution - 0128

    San Luis Potosí City, San Luis Potosí, 78200

  • Local Institution - 0095

    Veracruz, 91900

Other trials in Mexico

China8 sites
  • Local Institution - 0159

    Beijing, Beijing Municipality, 100005

  • Local Institution - 0190

    Chongqing, Chongqing Municipality, 400010

  • Local Institution - 0150

    Dalian, Liaoning, 116000

  • Local Institution - 0147

    Guangzhou, Guangdong, 510120

  • Local Institution - 0149

    Hefei, Anhui, 230071

  • Local Institution - 0146

    Shanghai, Shanghai Municipality, 200040

  • Local Institution - 0143

    Shenzhen, Guangdong, 518020

  • Local Institution - 0145

    Yiwu, Zhejiang, 322000

Other trials in China

Colombia8 sites
  • Local Institution - 0072

    Barranquilla, 080020

  • Local Institution - 0069

    Bogotá, 110221

  • Local Institution - 0063

    Bogotá, 111156

  • Local Institution - 0071

    Bucaramanga, Santander Department, 680003

  • Local Institution - 0070

    Cali, 760042

  • Local Institution - 0094

    Medellín, 050021

  • Local Institution - 0064

    Medellín, 050034

  • Local Institution - 0065

    Zipaquirá, 250252

Other trials in Colombia

Hungary8 sites
  • Local Institution - 0023

    Budapest, 1027

  • Local Institution - 0142

    Budapest, 1027

  • Local Institution - 0026

    Budapest, 1033

  • Local Institution - 0025

    Budapest, 1036

  • Local Institution - 0203

    Budapest, 1036

  • Local Institution - 0270

    Gyula, Bekes County, 5700

  • Local Institution - 0049

    Székesfehérvár, Fejér, 8000

  • Local Institution - 0068

    Zalaegerszeg, 8900

Other trials in Hungary

Brazil7 sites
  • Local Institution - 0219

    Curitiba, Paraná, 80030110

  • Local Institution - 0214

    Curitiba, Paraná, 80440-080

  • Local Institution - 0002

    Juiz de Fora, Minas Gerais, 36010-570

  • Local Institution - 0005

    Porto Alegre, Rio Grande do Sul, 90480-000

  • Local Institution - 0001

    Salvador, Estado de Bahia, 40150-150

  • Local Institution - 0108

    Santo André, São Paulo, 09060-870

  • Local Institution - 0109

    Vitória, Espírito Santo, 29055450

Other trials in Brazil

Czechia7 sites
  • Local Institution - 0018

    Ostrava, 722 00

  • Local Institution - 0208

    Pardubice, 530 02

  • Local Institution - 0225

    Prague, Praha 5, 150 06

  • Local Institution - 0097

    Prague, 12850

  • Local Institution - 0017

    Prague, 130 00

  • Local Institution - 0269

    Uherské Hradiště, Zlín, 68601

  • Local Institution - 0202

    Zlín, Zlín, 760 01

Other trials in Czechia

Australia6 sites
  • Local Institution - 0137

    Botany, New South Wales, 2019

  • Local Institution - 0136

    Camberwell, Victoria, 3142

  • Local Institution - 0211

    Hobart, Tasmania, 7000

  • Local Institution - 0220

    Phillip, Australian Capital Territory, 2606

  • Local Institution - 0133

    Westmead, New South Wales, 2145

  • Local Institution - 0132

    Woolloongabba, Queensland, 4102

Other trials in Australia

Chile6 sites
  • Local Institution - 0226

    Santiago, Santiago Metropolitan, 0

  • Local Institution - 0099

    Santiago, Santiago Metropolitan, 7500571

  • Local Institution - 0073

    Santiago, Santiago Metropolitan, 7501126

  • Local Institution - 0222

    Santiago, Santiago Metropolitan, 7510047

  • Local Institution - 0111

    Santiago, Santiago Metropolitan, 7640881

  • Local Institution - 0261

    Viña del Mar, Valparaiso, 2531172

Other trials in Chile

Taiwan5 sites
  • Local Institution - 0123

    Kaohsiung City, 833401

  • Local Institution - 0121

    Tainan, 704

  • Local Institution - 0122

    Tainan, 710

  • Local Institution - 0120

    Taipei, 110

  • Local Institution - 0124

    Taoyuan, 333423

Other trials in Taiwan

Ireland4 sites
  • Local Institution - 0101

    Dublin, 4

  • Local Institution - 0102

    Dublin, D15 X40D

  • Local Institution - 0103

    Galway, H91 TY80

  • Local Institution - 0104

    Manorhamilton, Leitrim, F91 X012

Other trials in Ireland

Italy4 sites
  • Local Institution - 0066

    Genova, 16132

  • Local Institution - 0062

    Pavia, 27100

  • Local Institution - 0096

    Udine, 33100

  • Local Institution - 0058

    Verona, 37134

Other trials in Italy

Russia4 sites
  • Local Institution

    Kemerovo, 650070

  • Local Institution

    Korolyov, 141060

  • Local Institution

    Saint Petersburg, 194214

  • Local Institution

    Yaroslavl, 150003

Other trials in Russia

Spain4 sites
  • Local Institution - 0021

    A Coruña, 15006

  • Local Institution - 0022

    Córdoba, 14004

  • Local Institution - 0019

    Madrid, 28046

  • Local Institution - 0020

    Sabadell, 08208

Other trials in Spain

Finland3 sites
  • Local Institution - 0013

    Helsinki, 00290

  • Local Institution - 0089

    Kuopio, 70100

  • Local Institution - 0119

    Turku, FI-20521

Other trials in Finland

France3 sites
  • Local Institution - 0077

    Chambray-lès-Tours, 37170

  • Local Institution - 0075

    Montpellier, 34295

  • Local Institution - 0074

    Paris, 75010

Other trials in France

United Kingdom3 sites
  • Local Institution - 0116

    Harlow, CM227NR

  • Local Institution - 0106

    Southampton, Hampshire, SO16 6YD

  • Local Institution - 0107

    Stoke-on-Trent, ST6 7AG

Other trials in United Kingdom

About this study

Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Being tested
Deucravacitinib, Placebo
Keywords
Biologic-Naive, BMS-986165, Deucravacitinib, Disease-modifying Anti-rheumatic Drugs, DMARDs, Joint Disease, Psoriatic Arthritis, PsA
Medical subject headings
Arthritis, Psoriatic, Joint Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DeucravacitinibDrug

    Also called BMS-986165

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Study groups in NCT04908202
Study groupRoleWhat they receive
DeucravacitinibExperimentalNot described
Receives: Drug: Deucravacitinib
PlaceboPlacebo comparatorNot described
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With ACR 20 Response at Week 16

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 16

Secondary outcomes (58)
  1. Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: < 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; >5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Measured: Baseline and Week 16

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Measured: Baseline and Week 16

  3. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 16

  4. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Measured: Baseline and Week 16

  5. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Measured: Week 16

  6. Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16

    Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:

    1. Tender joint count <= 1
    2. Swollen joint count <=1
    3. Psoriasis Area and Severity Index (PASI) <= 1 or body surface area (BSA) <= 3%
    4. Patient assessment of psoriatic arthiritis (PsA) pain <= 15
    5. Patient Global Assessment of PsA disease activity <= 20
    6. HAQ-DI <= 0.5
    7. Tender enthesial points <= 1

    Measured: Week 16

  7. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Measured: Baseline and Week 16

  8. Percentage of Participants Meeting Dactylitis Resolution at Week 16

    Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count => 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Measured: Week 16

  9. Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.

    Measured: Baseline and Week 16

  10. Percentage of Participants With ACR 20 Response up to Week 16

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 2, 4, 8, 12, and 16

  11. Percentage of Participants With ACR 50 Response up to Week 16

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 2, 4, 8, 12, and 16

  12. Percentage of Participants With ACR 70 Response up to Week 16

    The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 2, 4, 8, 12, and 16

  13. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Measured: Baseline and Week 2, 4, 8, 12, and 16

  14. Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.

    Measured: Baseline and Week 2, 4, 8, 12, and 16

  15. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 4, 8, 12 and 16

  16. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 4, 8, 12 and 16

  17. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Measured: Week 4, 8, 12 and 16

  18. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  19. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Measured: Week 4, 8, 12 and 16

  20. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \[R\]/left \[L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.

    Measured: Week 4, 8, 12 and 16

  21. Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16

    Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16:

    1. Tender joint count <= 1
    2. Swollen joint count <=1
    3. Psoriasis Area and Severity Index (PASI) <= 1 or body surface area (BSA) <= 3%
    4. Patient assessment of psoriatic arthiritis (PsA) pain <= 15
    5. Patient Global Assessment of PsA disease activity <= 20
    6. HAQ-DI <= 0.5
    7. Tender enthesial points <= 1

    Measured: Week 4, 8, 12, and 16

  22. Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  23. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  24. Percentage of Participants Meeting Dactylitis Resolution up to Week 16

    Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count => 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Measured: Week 4, 8, 12 and 16

  25. Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16

    The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  26. Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  27. Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  28. Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \[cm\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  29. Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16

    The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.

    Measured: Week 2, 4, 8, 12 and 16

  30. Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Measured: Baseline and Week 2, 4, 8, 12 and 16

  31. Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity.

    Measured: Week 2, 4, 8, 12 and 16

  32. Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity.

    Measured: Week 2, 4, 8, 12 and 16

  33. Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16

    The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  34. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16

    Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Measured: Baseline and Week 4, 8, 12 and 16

  35. Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16

    The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity

    Measured: Week 2, 4, 8, 12 and 16

  36. Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16

    BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5

    Measured: Week 2, 4, 8, 12 and 16

  37. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  38. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  39. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.

    Measured: Week 16

  40. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  41. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  42. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.

    Measured: Week 16

  43. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  44. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Week 16

  45. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96* standard deviation of the paired differences of change from baseline/ square root of (2*k); k is the number of reviewers and is default to 2 in this study.

    Measured: Week 16

  46. Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Baseline and Week 16

  47. Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Measured: Baseline and Week 16

  48. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  49. Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  50. Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  51. Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  52. Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  53. Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  54. Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  55. Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.

    Measured: Baseline and Week 4, 12 and 16

  56. Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16

    WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Measured: Baseline and week 16

  57. Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Measured: Baseline and week 4 and 16

  58. Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16

    The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Measured: Baseline and week 4, 12, and 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jun 2021
  2. Study start13 Jul 2021
  3. Primary completion10 Oct 2024
  4. Study completion3 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
670 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04908202
Sponsor's protocol ID
IM011-054
Other IDs
2023-506256-25, U1111-1259-9443, 2023
Status last verified
Sep 2026
First submitted
28 May 2021
Last updated
16 Oct 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in